ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年09月22日 08時50分
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America
オーストラリア・アデレード, 2020年09月22日 - (JCN Newswire) - The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions
Avance Clinical made the announcement at BioPharm America (September 21-24, 2020)
Avance Clinical's biotech clients now have the option to deploy the latest eClinical solutions to maximise the value of study data and deliver real-time visibility on study progress.
Avance Clinical CEO Yvonne Lungershausen said:
"Our Data Management team works with eClinical leaders such as Medrio to offer regulatory compliant and patient centric tools for rapid start-up and continual data flow. These tools improve patient engagement and data collection and allow Sponsors to stay informed at every step with Sponsor visible portals."
The Avance Clinical eClinical services include the following:
eSource
- Direct data capture of source data on site
- Forms customised by Avance Clinical Data Management team
- Edit checks built into forms; instant firing of queries once data is entered
- Option for data to be collected off-line and synced when on-line is available
- Fully integrated with Medrio EDC, data visible for Sponsor review instantly
- Remote monitoring and data review on ongoing basis
- Avance Clinical provision of tablets if required
eConsent
- Electronic consent including patient sign-off and investigator confirmation
- Customisable to include animations, videos and questions as required
- Forms customised by Avance Clinical Data Management team
- Link via email to patient
- Compatible with any device and internet system (smart phones, tablet, laptop, desktop)
- Integrated with Medrio EDC
- Link can be shared with HREC as part of submission package
ePRO
- Electronic capture of patient reported outcome, including diary data, dosing compliance, questionnaires, VAS/Pain scales
- Forms customised by Avance Clinical Data Management team
- Link via email to patient
- Options for emails and reminders at set times during the day or week
- Timezone adjusted to patient's location
- Compatible with any device and internet system (smart phones, tablet, laptop, desktop)
- Fully integrated with Medrio EDC, data visible for Sponsor review instantly
Glynn Morrish, Avance Clinical Director Biometrics said:
"Direct electronic capture of study information and the complimentary suite of solutions offered by Avance Clinical allows the company and its clients to maximise clinical trial efficiency and flexibility while ensuring data integrity is preserved. Our highly trained and experienced biometrics team are excited to continue to work at the forefront of innovation and technology and provide services that offer stability and robustness to studies being conducted in an ever-changing global environment."
Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.
Considering Australia? Contact us about your next study.
https://www.avancecro.com/eclinical-solutions/
About Avance Clinical www.avancecro.com
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact:
media@avancecro.com
Chris Thompson
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 22, 2024 22:42 JST
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 18, 2024 23:30 JST
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 18, 2024 17:29 JST
Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business
Nov 18, 2024 12:31 JST
Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round
Nov 18, 2024 09:25 JST
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 18:00 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
More Latest Release >>